Several analysts have recently updated their ratings and price targets for Monopar Therapeutics (NASDAQ: MNPR):7/23/2026 – Monopar Therapeutics was given a new $125.00 price target by UBS Group AG. 7/22/2026 – Monopar Therapeutics had its price target raised by HC Wainwright from $105.00 to $125.00. 7/17/2026 – Monopar Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings. 6/30/2026 – Monopar Therapeutics had its price target raised by BTIG Research from $104.00 to $117.00. Featured StoriesReceive News & Ratings for Monopar Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.